A 9 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study Of Pregabalin (BID) In Subject With Posttraumatic Peripheral Neuropathic Pain.
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2012
At a glance
- Drugs Pregabalin (Primary)
- Indications Anxiety; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Nov 2012 Planned patient number is 260 according to European Clinical Trials Database record.
- 01 Aug 2010 Results have been published in the European Journal of Neurology.
- 02 May 2009 Primary endpoint results presented at the 61st Annual Meeting of the American Academy of Neurology